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A number of recent studies have investigated the role of de novo mutations in various neurodevelopmental and neuropsychiatric dis-
orders. These studies attempt to implicate causal genes by looking for an excess load of de novo mutations within those genes. Current
statistical methods for assessing this excess are based on the implicit assumption that all qualifying mutations in a gene contribute
equally to disease. However, it is well established that different mutations can have radically different effects on the ultimate protein
product and, as a result, on disease risk. Here, we propose a method, fitDNM, that incorporates functional information in a test of excess
de novo mutational load. Specifically, we derive score statistics from a retrospective likelihood that incorporates the probability of a
mutation being damaging to gene function. We show that, under the null, the resulting test statistic is distributed as a weighted sum
of Poisson randomvariables andwe implement a saddlepoint approximation of this distribution to obtain accurate p values. Using simu-
lation, we have shown that our method outperforms current methods in terms of statistical power while maintaining validity. We have
applied this approach to four de novo mutation datasets of neurodevelopmental and neuropsychiatric disorders: autism spectrum dis-
order, epileptic encephalopathy, schizophrenia, and severe intellectual disability. Our approach also implicates genes that have been
implicated by existingmethods. Furthermore, our approach provides strong statistical evidence supporting two potentially causal genes:
SUV420H1 in autism spectrum disorder and TRIO in a combined analysis of the four neurodevelopmental and neuropsychiatric disor-
ders investigated here.Introduction
Germline de novo mutations are genetic alterations that
occur, for the first time, in the gametes that make up an
individual and, as such, are not inherited from parents.
De novo mutations generally occur at a rate of approxi-
mately 1.18 3 108 per locus per generation.1,2 Because
de novo mutations generally have not been pruned out
of the population by purifying selection, they are often
more likely to be considered associated with sporadic
genetic-disease risk than are inherited variants.3–5 Next-
generation-sequencing technologies have made the detec-
tion of de novo mutations and the investigation of their
role in human disease feasible. Indeed, de novo mutations
have been reported to play an important role in several
complex diseases, including severe intellectual disability
(ID),6 epileptic encephalopathy (EE [MIM: 308350]),7 and
autism spectrum disorder (ASD).8,9
One goal of de novo mutation studies is to identify
disease-associated genes by contrasting observed and
expected patterns of de novo mutations in affected indi-
viduals, i.e., find genes with more de novo mutations
among a cohort of similarly affected individuals than
one would expect to see in a random sample of individuals
from the general population. How one characterizes this
expected distribution is critical, and the distribution obvi-
ously changes with the size and mutability of the gene.
Because de novo mutations tend to originate indepen-
dently of one another, recent work has characterized the
expected distribution with a Poisson model, in which
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sent the gene-specific mutation rate.7 This approach,
which we refer to as the ‘‘Poisson test,’’ has already been
successfully applied to a number of de novo mutation
studies, including studies of EE7 and ASD.10
The Poisson test, however, implicitly assumes that all
de novo mutations found within the gene have the same
influence on disease. It is well established that different
mutations can have radically different impacts on the ulti-
mate protein product, leading to vastly different effects on
disease. Thus, when looking for shifts from expectation in
the distribution of de novo mutations in an affected sam-
ple, considering the potential impact of those mutations
could be important given that one might see a shift only
in certain classes of mutations. There is some evidence
that this is the case. For example, in the de novo mutation
studies of ASD, although researchers could not establish a
significant overall excess of de novo mutations given their
cohort sizes, they did observe that the total number of
non-synonymous de novo SNVs was significantly greater
in probands than in their unaffected siblings.9,11 Another
study of ASD has reported finding an increased frequency
of loss-of-function (LOF) mutations in probands relative
to that in their unaffected siblings.8 Similar results have
been observed in the study of severe ID; Rauch et al. found
a higher proportion of individuals with LOF mutations
among an affected group than they did among those in a
control group.12 These results suggest that a mutation’s
predicted impact on gene function is an important factor
in assessing the ‘‘burden’’ of de novo variants within
a gene.C 27710, USA; 2School of Medicine, Duke University, Durham, NC 27708,
0032, USA
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In this manuscript, we propose a de novo mutational
load test that incorporates predictions of mutation func-
tionality. In brief, the contribution of each de novo muta-
tion is weighted by its predicted damage to the ultimate
gene product with which it is affiliated. Weighting in this
way is expected to add considerable power when damaging
mutations in affected individuals are enriched over expec-
tation based on the mutational process of the gene being
considered.
There aremultiple variant-annotation tools that can pro-
vide in silico predictions of the most likely functional
impact of individual de novo mutations. For example,
PolyPhen-2, SIFT, and others can be used to estimate the
effect ofmissensemutations.13,14 SIFTcalculates the proba-
bility that an amino acid at a position is tolerated,whereas a
PolyPhen-2 score is the naive Bayes posterior probability
that a givenmutation is damaging. Bothmethods quantita-
tively characterize the predicted functionality of these mu-
tations. More recently, attempts have been made to assess
variant functionality across the genome. For example, the
recently developedC scores can be used to predict the effect
of any possible human single-nucleotide variant or indel,
even those found in introns or intergenic regions.15
One approach to incorporating variant functional
impact in tests of de novo enrichment is to do so qualita-
tively by only considering certain classes of variation in
the analysis. For example, in their TADA-denovo method,
He et al.16 include only LOF mutations and missense mu-
tations predicted to be probably damaging by PolyPhen-2.
This approach is likely to work well if the truly damaging
mutations are strongly clustered into the classes of varia-
tion incorporated in the statistic. However, in the absence
of such strong clustering, this approach can ignore impor-
tant mutations leading to a loss of power. Along these
lines, we note that 21% of ClinVar pathogenic missense
variants (i.e., missense mutations annotated as disease
causal) would not be annotated as probably damaging.
In the next section, we develop a method that quantita-
tively incorporates functional information in a test of
excess de novo mutational load (fitDNM) and show that,
under the null, the test is distributed as a weighted sum
of independent Poisson random variables. Interestingly,
the cumulative distribution function of the resulting distri-
bution is not available in closed form, and we show how
p values can be accurately estimated with a saddlepoint
approximation. In the Results section, we compare our
test with the Poisson test and TADA-denovo method via
simulations. Finally, we apply our method to analyze
de novo mutations in 1,717 samples ascertained for an
EE, ASD, severe ID, or schizophrenia (SZ) diagnosis.Material and Methods
General Framework
The goal of a de novo load analysis is to identify disease genes by
detecting an unexpected clustering of de novo mutations in theThe Amergenes of affected individuals. In this section, we lay out a frame-
work for an excess de novo load test that formally incorporates
variant functionality. We begin by making three simplifying
assumptions. First, we consider only loci that are non-polymor-
phic in the parents. Polymorphic loci represent a small fraction
of the genome and are less likely to be functionally significant.
Second, we assume that having two de novo mutations at the
same site within an individual is rare enough to be negligible.
Finally, we assume that the effect of a de novo mutation on
offspring disease risk is the same regardless of whether the muta-
tion is maternally or paternally derived; i.e., we ignore parent-
of-origin effects. Under these three assumptions, the problem is
greatly simplified, given that there are only four possible events
that can occur in any given trio at any given site: there is either
no mutation, so that the offspring retains two copies of the
reference base, or there is a newmutation on one of the offspring’s
haplotypes from the reference base to one of three alternative
bases at that reference site. Because the reference base is poten-
tially different at each locus l, we denote these four possible events
as xl0; xl1; xl2, and xl3, where xl0 represents the no-mutation event
and xl1; xl2, and xl3 represent de novo mutations from the refer-
ence to the three alternative bases. For example, if, at locus l,
the reference base was A, xl0 would represent the null mutation
from A/ A, and xl1; xl2; and xl3 could represent de novo muta-
tions A / C, A / G, and A / T, respectively. Let Xil be the
random variable denoting which of these events are observed at
locus l in trio i.
Characterizing the Distribution of De Novo Mutations at a Single Locus
We begin with two definitions that will help clarify the develop-
ment below. First, we define a mutation to be ‘‘damaging’’ when
it can destroy or severely impact gene function; i.e., it causes the
gene to become ‘‘dysfunctional.’’ Second, we define a gene to be
‘‘pathogenic’’ when the presence of a dysfunctional gene product
increases disease risk.
We characterize the distribution of de novo mutations in an
affected individual at a single locus; i.e., PrðXil ¼ xlkjAi ¼ 1Þ, where
Ai ¼ 1, denotes that the offspring in trio i is affected. To simplify
the notation, we define llkhPrðXil ¼ xlkjAi ¼ 1Þ. Using Bayes’
theorem and the total law of probability, we get
llk ¼ plkPrðAi ¼ 1 jXil ¼ xlkÞP3
k¼0 plkPrðAi ¼ 1 jXil ¼ xlk Þ
; (Equation 1)
where plk ¼ PrðXil ¼ xlkÞ and is the probability of mutation
event xlk per individual in the general (unselected by disease)
population.
The impact of mutations on disease is most likely mediated
by protein function, i.e., by the effect of a mutation on protein
structure or expression. Our approach attempts to leverage
what is known about the functional impact of specific muta-
tions on protein function into a test of association between
mutation and disease. To do so, we expand the risk of a
mutation, i.e., PrðAi ¼ 1jXil ¼ xlkÞ, to incorporate the probability
that the mutation is damaging to protein function. Specifically,
we write
PrðAi ¼ 1 jXil ¼ xlkÞ ¼
X1
d¼0
PrðAi ¼ 1 jXil ¼ xlk;D ¼ dÞ
3PrðD ¼ d jXil ¼ xlkÞ;
where D is an indicator of whether protein function is deleteri-
ously impacted ðD ¼ 1Þ or not ðD ¼ 0Þ. We assume that once we
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no longer informs on disease risk, i.e., PrðAi ¼ 1jXil ¼ xlk;D ¼ dÞ ¼
PrðAi ¼ 1jD ¼ dÞ. Let g denote the relative risk of an individual
being affected with dysfunctional protein product in comparison
to the likelihood of an individual having normal protein,
i.e., g ¼ PrðAi ¼ 1jD ¼ 1Þ=PrðAi ¼ 1jD ¼ 0Þ. Thus, by factoring
out PrðAi ¼ 1jD ¼ 0Þ and rearranging terms, we have that
PrðAi ¼ 1jXil ¼ xlkÞ ¼ PrðAi ¼ 1jD ¼ 0Þ½1þ ðg 1Þrlk;
where rlkhPrðD ¼ 1jXil ¼ xlkÞ. Plugging this back into Equa-
tion 1, we have
llk ¼ ½1þ ðg 1ÞrlkplkP3
k¼0½1þ ðg 1Þrlk plk
: (Equation 2)
Note that Equation 2 allows us to characterize the distribu-
tion of de novo mutations at locus l in terms of the risk
parameter g; the probability that the mutation is damaging to
protein function, rlk; and the probability of observing such a mu-
tation in an unselected sample, plk. The parameter of interest is g,
whereas rlk and plk are estimated from external data and are
assumed to be known. We will discuss how rlk and plk are esti-
mated below.
Assume we have a sample of nl trios at locus l, and let
Nlk ¼
Pnl
i¼1IðXil ¼ xlkÞ and k ¼ 0; 1; 2; or 3 where I is an indicator
function. We let the number of trios be a function of l to account
for the fact that different sites might lead to a different subset of
the total sample size being ‘‘callable,’’ i.e., to have adequate
coverage and quality characteristics so that a de novo mutation
would have a reasonable chance of being called if in fact it existed.
Furthermore, when testing genes on the X chromosome, in order
to account for differences in the number of chromosomes between
males and females, we replace nl above with nl ¼ ðnlm=2Þ þ nlf ,
where nlm and nlf are the number of callable male offspring trios
and callable female offspring trios, respectively, at locus l. It is
not hard to see that the distribution of de novo mutations at
locus l is multinomial, i.e.,
ðNl0;Nl1;Nl2;Nl3Þ  Multinomialðnl; ll0; ll1; ll2; ll3Þ: (Equation 3)
The de novo mutation rate, plk; where k ¼ 1, 2, or 3, is often
around 108 per locus per meiosis.1 As a result, ll1; ll2; and ll3
will be far smaller than ll0. In this situation, it can be shown
that ðNl1;Nl2;Nl3Þ can be accurately approximated by three inde-
pendent Poisson random variables with means nlll1;nlll2; and
nlll3.
17 We let ðnl0;nl1;nl2;nl3Þ denote observed realizations of
the random variables ðNl0;Nl1;Nl2;Nl3Þ:
Gene-Level Test of Excess De Novo Load
Equations 2 and 3 allow us to characterize the distribution of
de novo mutations at a given locus among trios sampled on the
basis of the offspring being affected. In order to derive a gene-level
test, we characterize the distribution of de novo mutations
throughout a gene. Note that ‘‘gene’’ here is being used rather
generically and could include both coding-sequence sites as well
as other sites thought to contribute to gene function (regulatory
sites, splice sites, etc.), as well as collections of biologically grouped
genes. Assume there are p sites across the gene. Given that de novo
mutations are thought to occur independently across loci,7,18 by
using the Poisson approximation highlighted above, we find
that the likelihood can be written as
Yp
l¼1
Y3
k¼1
ðllknlÞnlk ellknl
nlk!
; (Equation 4)
where llk is given by Equation 2. Taking the log of Equation 4,
differentiating with respect to g, and evaluating under the null hy-274 The American Journal of Human Genetics 97, 272–283, August 6pothesis that the gene is not pathogenic, i.e., g ¼ 1, leads to the
score statistic
Sg ¼
Xp
l¼1
X3
k¼1
wlknlk 
Xp
l¼1
X3
k¼1
wlkplknl; (Equation 5)
where wlk ¼ rlk 
P3
k¼0rlkplk . Note that the second term of Sg is
made up of known parameters and can be considered fixed. Under
the null hypothesis, the first term of Sg, i.e.,
T ¼
Xp
l¼1
X3
k¼1
wlknlk; (Equation 6)
is a realization of a weighted (by the known weights wlk, where
k ¼ 1, 2, or 3) sum of independent Poisson random variables,
and a test (fitDNM) of excess de novo load can be constructed in
terms of the quantiles of this distribution.
Saddlepoint Approximation for Null Distribution of Excess De Novo
Load Test
Interestingly, we could not find an analytic method for computing
cumulative probabilities for a weighted sum of independent
Poisson random variables. Though a number of approximation
methods have been proposed,19 they are based on moment
matching and can be quite inaccurate in the extreme tails of the
distribution. Because we are interested in genome-wide inference,
in order to meet multiple testing thresholds, we are often inter-
ested in accurately estimating p values in the extreme tail (on
the order of 106), making such approaches a poor choice. Because
the cumulant generating function (CGF) is readily available for the
weighted sum of independent Poisson random variables, both
Edgeworth and saddlepoint approximations are possible. How-
ever, saddlepoint approximations have a decided advantage in
our application given that Edgeworth approximations can only
control the absolute error of the approximation, whereas saddle-
point approximations can control the relative error. This makes
the saddlepoint approximation far more accurate in the tail. As a
result, we have developed a saddlepoint approximation of the
null distribution of our proposed statistic. Details can be found
in Appendix A.
Mutation-Rate and Variant-Functionality Score Estimation
Both themutation rates, i.e., the plk values, and the probabilities of
a mutation functionally impacting the gene, i.e., the rlk values,
were estimated from external data and, thus, were assumed to be
known and fixed. The locus-specific mutation rate per generation,
plk ,was computed on the basis of local sequence context
2 and the
average de novo mutation rate (1.18 3 108).1 Specifically, we
began with a trinucleotide-based mutation matrix (provided by
Drs. Shamil Sunyaey and Paz Polak) that characterizes the relative
mutation rate of any base given its immediate flanking bases. We
then derived locus-specific mutation rates by calibrating the rela-
tive rates so that, when integrated over the entire human reference
genome, the average human de novo mutation rate (1.18 3 108)
was obtained. In these analyses, we computed the de novo
mutation rates for all possible non-null transitions. For example,
in a locus with reference base A, we computed the mutation rate
for alleles T, C, and G.
We used the following approach to estimating the rlk values.
For loss-of-function single-nucleotide-substitution mutations pre-
dicted by SnpEff,20 such as gain or loss of stop codon mutations,
mutations in a canonical splice site, etc., we set rlk ¼ 1. We set
rlk ¼ 0 for synonymousmutations. In all missense cases, rlk was set
by PolyPhen-2 (HumDiv) to the probability that the mutation is
damaging output.13 Whenmultiple scores for different transcripts, 2015
were available, the maximum score was used. When PolyPhen-2
predictions were not available, we removed that locus from our
analysis. Note that the analyses presented here did not consider
frameshift or codon indels because the mutation rates for these
mutations are currently difficult to estimate reliably. However,
when reliable estimates become available, our approach will be
able to easily incorporate these classes of variation.
Simulation Studies
Simulation studies were performed to evaluate the accuracy of the
saddlepoint approximation and to compare the power of our pro-
posed de novo load test with that of the standard Poisson test.
Accuracy of Saddlepoint Approximation
In order to evaluate the performance of the saddlepoint approxi-
mation in a realistic setting, we based our simulations on a real,
average-sized gene, GABRB3 (MIM: 137192). GABRB3 has 1,573
protein-coding loci according to the consensus coding sequence
(CCDS) project (CCDS release 14; Genome Reference Consortium
GRCh37), whereas the mean and median sizes of genes across the
genome are approximately 1.7 kbp and 1.3 kbp, respectively. Both
the plk and the rlk values (and, hence, the wlk values) used in the
simulation were defined by those observed in GABRB3. For each
simulated dataset, we generated Nlk, i.e., the number of mutations
of type k at locus l, by sampling from a Poisson distribution with
mean nplk where n is the total number of trios being simulated.
Given the Nlk values, we generated a weighted sum of Poisson
random variables under the null by Y ¼Pml¼1P3k¼1wlkNlk.
Repeating this process 108 times allowed us to reliably estimate
the quantiles of the null distribution of Y (down to quantiles on
the order of 106). We compared our saddlepoint approximation
to these empirical quantiles in order to evaluate the accuracy of
the approximation. Specifically, we used the relative error defined
as the ratio of the absolute difference between p values estimated
by the saddlepoint approximation and those derived from the
empirical distribution of Y to the minimum of these two p values.
Power and Type I Error
Here, we compared the power and type I error of fitDNM to those
of the Poisson test and TADA-denovo. To get a broader perspective
on how incorporating functional information affects the perfor-
mance of the test, we modeled our simulations on the basis of
three genes (TSGA13, GABRB3, and KIRREL3 [MIM: 607761]) rep-
resenting a spectrum of gene size. We also generated a hypotheti-
cal gene, which has an exact size of 1.5 kbp (corresponding to
average gene size across the genome) and for which PolyPhen-2
scores and mutation rates were randomly sampled from the
222 genes observed to harbor de novo mutations in our data.
We based our simulated sample sizes (ranging from 150 to 2,000
samples) on the number of trios used in the real data analysis
described below. We simulated the data prospectively, simulating
de novomutations in the offspring of individuals from the general
population, determining disease status on the basis of those
mutations, and then sampling the given number of trios with
affected offspring. Specifically, for each individual in the general
population, de novo mutations (or the null mutation) at
each of p sites were generated from a multinomial distribution,
i.e., Xl  Multinomialð2;pl0;pl1;pl2;pl3Þ, where the plk values
were based upon the actual mutation rates of the gene being
simulated. We then simulated whether each potential mutation
was damaging, Dlk, via Dlk  BernoulliðrlkÞ, where the rlk
values are the PolyPhen-2 scores for the kth-type mutation at
site l in the gene being simulated. The disease status of the
offspring was then sampled from a Bernoulli distributionThe Amerwith mean expit½aþ Ppl¼1P3k¼0bDlkIðXl ¼ xlkÞ where we took
a ¼ log½h=ð1 hÞ so that the prevalence was approximately h.
We repeated the above steps until we had the desired number of
affected samples. Note that the above disease model reflects a
dominant disease model so that the presence of a damaging muta-
tion in a causal gene leads to a similar increase in disease risk. We
chose b from log(500) to log(2,000), i.e., almost fully penetrant, to
reflect estimates derived from real data7 andmodified disease prev-
alence, from 0.05% to 1%, so as to target the 50% power region of
the power curve where relative power differences can be observed.
Misspecification of Variant Functional Impact
We used simulations to compare our method to the Poisson test
and TADA-denovo when the estimated functional impact of a sub-
set of mutations is misspecified. We considered two approaches to
misspecifying the functional impact of mutations. First, we began
by simulating damaging mutations by using PolyPhen-2 scores, as
described above. However, we then introduced noise into the
functional impact scores used in the actual test statistic. Specif-
ically, we generated the scores from a normal distribution with
the true PolyPhen-2 score as the mean. We considered different
variances, from 0.3 to 3, for this normal distribution and truncated
values at 0 and 1. For the second scenario, we considered a situa-
tion in which the true probability that a mutation is damaging
is discrete, such that only LOF mutations and 50% of missense
mutations with a PolyPhen-2 score R0.957 are simulated as
damaging. However, when we analyzed the simulated data, we
used the quantitative PolyPhen-2 score in the test.
Comparison with Other Methods
We compared ourmethod, fitDNM, to the Possion test7 and TADA-
denovo.16 Both methods require gene-specific mutation rates, i.e.,
the sum of the mutation rate of all possible mutations in the call-
able region of each gene. For TADA-denovo, in order to improve ac-
curacy, the fraction of mutations in each category (LOF, probably
damaging, etc.) is estimated for each gene separately. For all other
parameters required by TADA-denovo, we adopted their default
values. Null simulations of the Bayes factor were used to compute
p values for TADA-denovo. When evaluating type I error, 10,000
simulation replicates were used. When evaluating power and in
analyses of neurodevelopmental disease, 108 replicates were used.Results
Simulation Studies
Accuracy of the Saddlepoint Approximation
Figure 1 presents the relative error comparing p values
computed via the saddlepoint approximation to empirical
p values computed via simulation. The relative error
is e ¼ ðpemp  pestÞ=minðpemp;pestÞ. When e is close to
zero, the approximation is perfect. As can be seen in
Figure 1, e is, in fact, close to zero and ranges from 1 to
1 for both small (n ¼ 150) and large (n ¼ 2,000) sample
sizes. This confirms the high accuracy of the saddlepoint
approximation and implies that the saddlepoint approxi-
mation yields p values of the same magnitude as those
computed empirically, even in the extreme tail of the
p value distribution (i.e., %106).
Power and Type I Error
Table 1 summarizes the results under the null hypothesis
(i.e., the gene is not associated with disease) for the Poissonican Journal of Human Genetics 97, 272–283, August 6, 2015 275
Figure 1. Relative Errors of Saddlepoint
Approximation
Relative error ¼ ðpemp  pestÞ=minðpemp;
pestÞ, where pemp is the p value estimated
from a simulation with 108 replicates and
pest is the p value estimated by saddlepoint
approximation.test, fitDNM, and TADA-denovo. All tests maintain the cor-
rect type I error rate. However, because these tests are
highly discrete, it is impossible to guarantee a test with
an exact a-level; instead, we can only guarantee that a test’s
type I error is at most a. As a result, these tests appear to be
somewhat conservative in most situations. Figure S1 gives
a quantile-quantile (Q-Q) plot for fitDNM for a simulation
(KIRREL13, n ¼ 150) under the null hypothesis. We also
include simulation-based 95% confidence intervals, con-
structed with 10,000 replicates. Note that even though
the Q-Q plot does not follow the 45 line, due to the
discreteness of the statistic, it falls well within the
confidence interval, confirming that the null distribution
for the statistics is correct. In Table 2, we compared
power across different genes and sample sizes. We have
found that incorporating variant functionality improves
statistical power across most scenarios. For example,
when using 150 trios and analyzing TSGA13, we found
that our fitDNM yielded a >2-fold increase of power
over the Poisson test and that it yielded similar resultsTable 1. Type I Error Rates from 10,000 Simulations
Method Gene Gene Size (bp)
a ¼ 0.05 a ¼ 0
n ¼ 150 n ¼ 500 n ¼ 1,000 n ¼ 1,500 n ¼ 1
Poisson TSGA13 856 0.0039 0.0121 0.0250 0.0367 0.003
GABRB3 1,573 0.0074 0.0241 0.0021 0.0036 0.000
KIRREL3 2,440 0.0132 0.0469 0.0041 0.0097 0
example 1,500 0.0071 0.0206 0.0441 0.0025 0.000
fitDNM TSGA13 856 0.0030 0.0085 0.0177 0.0247 0.003
GABRB3 1,573 0.0050 0.0166 0.0328 0.0462 0.004
KIRREL3 2,440 0.0091 0.0313 0.0449 0.0389 0.003
example 1,500 0.0048 0.0153 0.0325 0.0449 0.004
TADAa TSGA13 856 0.0015 0.0035 0.0071 0.0094 0.001
GABRB3 1,573 0.0026 0.0097 0.0182 0.0291 0.002
KIRREL3 2,440 0.0064 0.0227 0.0454 0.0074 0.000
example 1,500 0.0027 0.0082 0.0197 0.0274 0.002
Because all of these three tests are constructed on the basis of discrete distribution, it is impossible to get the ty
most situations. Abbreviation is as follows: TADA, TADA-denovo.
aParameters are gamma.mean.dn ¼ (20, 4.7), beta.dn ¼ (1, 1), and pi0 ¼ (0.94).
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In our simulation, neither TADA-
denovo nor the Poisson test com-
pletely dominates the other. Note
that, in our simulation, disease isquite rare (prevalence % 1%) and damaging mutations
are assumed to be almost fully penetrant, therefore the
absolute power observed in our simulations will not be
reflective of the power that would be obtained for a com-
mon, complex disease. Nevertheless, conclusions about
the relative power of the approaches, which is our focus
here, should remain valid.
Type I Error and Power when the Functional Impact of Variants Is
Misspecified
Figures S2 and S3 show the type I error rates of fitDNM
when variant deleteriousness is misspecified. As can be
seen, the type I error rates are well controlled. This is not
unexpected. When the gene is not associated with the dis-
ease risk, i.e., g ¼ 1 in Equation 2, llk ¼ plk and is not a
function of rlk. Thus, under the null hypothesis, the ex-
pected value of nlk in Equation 5 will be plknl, and we see
that the score equation has mean zero regardless of the
weights (i.e., the rlk values), implying that the test is
robust, in terms of controlling type I error, to misspecifica-
tion of the functional impact of variants. Figure 2 presents.005
50 n ¼ 500 n ¼ 1,000 n ¼ 1,500
9 0.0001 0.0007 0.0010
3 0.0005 0.0021 0.0036
0.0005 0.0041 0.0004
1 0.0003 0.0014 0.0025
0 0.0062 0.0039 0.0050
3 0 0.0008 0.0013
3 0.0005 0.0017 0.0032
6 0.0043 0.0006 0.0013
5 0.0005 0.0014 0.0023
6 0.0024 0.0039 0.0005
7 0.0025 0.0010 0.0018
7 0.0011 0.0037 0.0005
pe I error rates exactly equal to the nominal level at
Table 2. Power Comparison
Gene
n ¼ 150 n ¼ 500 n ¼ 1,000 n ¼ 1,500
Poisson fitDNM TADA Poisson fitDNM TADA Poisson fitDNM TADA Poisson fitDNM TADA
TSGA13a 0.131 0.352 0.143 0.442 0.465 0.137 0.326 0.328 0.098 0.180 0.332 0.053
GABRB3b 0.376 0.458 0.335 0.376 0.593 0.469 0.481 0.660 0.414 0.512 0.562 0.453
KIRREL3c 0.538 0.533 0.398 0.363 0.561 0.305 0.484 0.677 0.533 0.545 0.705 0.454
Exampled 0.455 0.517 0.352 0.596 0.588 0.407 0.343 0.545 0.261 0.490 0.533 0.367
Abbreviation is as follows: TADA, TADA-denovo.
aParameters (sample size/prevalence/OR) used in each scenario for TSGA13: 150/0.0005/1,000; 500/0.0015/1,000; 1,000/0.005/1,000; 1,500/0.008/1,000.
bParameters used in each scenario for KIRREL3: 150/0.001/500; 500/0.07/500; 1,000/0.01/500; 1,500/0.015/500.
cParameters used in each scenario for GABRB3: 150/0.0005/800; 500/0.002/500; 1,000/0.005/500; 1,500/0.008/500.
dParameters used in each scenario for the example: 150/0.001/2,000; 500/0.002/500; 1,000/0.008/1,500; 1,500/0.01/1,500.the power of fitDNM when the functional impact of vari-
ants is misspecified; KIRREL3 and a sample size of 500 is
used as an example. Figure 2A is the receiver operator char-
acteristic (ROC) curve for the classifier based on the simu-
lated PolyPhen-2 scores. Both fitDNM and TADA-denovo
are influenced by the misspecification of the impact of
missense mutations. The power of fitDNM is positively
associated with the area under the ROC curve: the more ac-
curate the scores, the higher the power of fitDNM.We note
that fitDNM has higher power than the Poisson test even
when the correlation between the misspecified score and
the probability of the mutation being damaging is around
0.6. The simulations based on other genes with different
sample sizes are summarized in Figure S4. As can be seen,
even in the worst scenario where the fitDNM has similar
power to the Poisson test, we only see a modest loss of
power when the correlation between the misspecified
score and the probability of the mutation being damaging
is less than 0.6.
Table 3 displays the power when the true probability
that a mutation is damaging is discrete (i.e., LOFmutations
and 50% of missense mutations with a PolyPhen-2
score R0.957 are simulated as damaging). In addition to
fitDNM, which uses the quantitative PolyPhen-2 scores,
we also, for comparison, present a test (fitDNM-true) in
which the weights follow the true probability of being
damaging, i.e., 0.5 if the PolyPhen-2 score is R0.957
and 0 if otherwise. All methods that utilize estimates of
variant functionality have a higher power than the un-
weighted Poisson test. fitDNM and TADA-denovo show
very similar statistical power, even though the simulation
model mimics the weighting scheme used by TADA-
denovo. Unsurprisingly, using the true weights (fitDNM-
true) yielded the highest power.
Application to Four Neurodevelopmental De Novo
Mutation Studies
Neurodevelopmental Disease Samples
We applied fitDNM, TADA-denovo, and the Poisson test to
trios affected by four neurodevelopmental diseases: 264 by
EE,7 151 by severe ID,12,21 354 by SZ,22–24 and 948 by
ASD.8–10,25 These datasets have been previously analyzedThe Amerin a number of ways. Many of the earlier studies simply re-
ported genes that were recurrently hit with de novo muta-
tions. For example, Rauch et al. highlighted STXBP1 (MIM:
602926), SCN2A (MIM: 182390), and SYNGAP1 (MIM:
603384) as being hit by de novo mutations more than
once in their study of 45 severe-ID-affected trios;12 Girard
et al. did not find any recurrently hit genes in their study
of 14 SZ-affected trios;24 Gulsunner et al. identified one
gene, CACNA1I (MIM: 608230), that was hit more than
once across 105 SZ-affected trios.23 This recurrently-hit-
gene approach does not account for gene size, mutability,
or even the size of the samples being investigated. To
deal with this, Neale et al.25 developed a simulation frame-
work to characterize the null distribution of the number of
de novo mutations found within a gene across a given set
of trios and that explicitly accounts for gene size, muta-
bility, and sample size. Their analysis failed to support
any gene as a conclusive risk factor in their study of 175
ASD-affected trios. More recently, the Poisson test has
been used to confidently implicate four genes (SCN1A
[MIM: 182389], STXBP1, GABRB3, and CDKL5 [MIM:
300203]) as significantly enriched for de novo mutations
in 264 EE-affected trios.7 The Poisson test was also used
to implicate NTNG1 (MIM: 608818) as involved in ASD
risk among 189 trios.10
In the analyses that follow, we define a gene as signifi-
cantly associated with the disease if it has a p value less
than 2.76 3 106, i.e., the Bonferroni significance
threshold required when testing 18,116 genes with an
overall family-wise error rate of 0.05. Table 4 lists genes
designated as significantly associated by any test. Note
that all genes identified by the Poisson test are also impli-
cated by fitDNM and TADA-denovo. Furthermore, both
fitDNM and TADA-denovo identified an additional, signif-
icantly associated gene: SUV420H1 (MIM: 610881) for
ASD, which was underpowered to achieve genome-wide
significance by the Poisson test.26,27 The mutations are
summarized in Table S2 and Figure S4.
Neurodevelopmental and neuropsychiatric disorders
co-occur far more often than can be explained by
chance.28 For example, familial studies show that children
whose mother has SZ, bipolar disorder, or unipolar majorican Journal of Human Genetics 97, 272–283, August 6, 2015 277
Figure 2. The Power of fitDNM when Variant Deleteriousness Is Misspecified
The left panel is the ROC curve for different deleterious predictions, and the right panel is the statistical power for corresponding mis-
specified deleteriousness. The dashed horizontal line indicates the power for the Poisson test.depression have a significantly increased risk of ID.29
Furthermore, individual copy-number variants have been
implicated in multiple neurodevelopmental disorders.28
These studies suggest that there are shared genetic compo-
nents among different neurodevelopmental and neuropsy-
chiatric disorders and motivate an analysis that combines
samples across neurodevelopmental disorders. Hence, we
also conducted an analysis that combined the EE-, ID-,
SZ-, and ASD-affected trios into one dataset, resulting in
1,717 total trios. In 1,226 of these trios, the affected child
was male, and in 491 of the trios, the affected child was
female. Consistent with the individual disease-based ana-
lyses, in the combined neurodevelopmental cohort, all
genes identified by the Poisson test and TADA-denovo
were also implicated by the fitDNM test. The Poisson test
implicated four genes, SCN1A, SCN2A, STXBP1, and
GABRB3, whereas fitDNM implicated these and two others,
CDKL5 and TRIO (MIM: 601893). Of particular note,
SCN2A and TRIOwere not implicated in any individual dis-
ease, but we found them to be significantly associated with
neurodevelopmental and neuropsychiatric disorders as a
collective set. Both SCN2A and TRIO had similar patterns
of de novo mutations across the various disorders. ForTable 3. Power Comparison under Categorical Deleteriousness
Gene
n ¼ 150
Poisson fitDNM TADA fitDNM-tru
TSGA13a 0.153 0.400 0.399 0.365
GABRB3b 0.372 0.522 0.489 0.524
KIRREL3c 0.325 0.325 0.334 0.526
Abbreviation is as follows: TADA, TADA-denovo.
aParameters (sample size/prevalence/OR) used in each scenario for TSGA13: 150/
bParameters used in each scenario for GABRB3: 150/0.0005/5,000; 500/0.002/5,
cParameters used in each scenario for KIRREL3: 150/0.0015/3,000; 500/0.005/3,0
278 The American Journal of Human Genetics 97, 272–283, August 6SCN2A, three de novo mutations were found in ASD-
affected trios, two in severe ID-affected trios, and two in
EE-affected trios. The role of the sodium-channel protein
subunit SCN2A in neurodevelopment has long been estab-
lished.30–33 For TRIO, two de novo mutations were found
in trios affected by ASD, two in trios affected by severe
ID, and one among those affected by EE. De Rubeis
et al.34 report TRIO as a possible risk gene for ASD by
combining information from de novo mutations and in-
herited variants in the TADA-denovo framework, assuming
a false discovery rate of 10%. Here, we implicate the pres-
ence of de novo mutations within TRIO as an important
risk factor across a number of neuropsychiatric disorders
at the more stringent 5% family-wise error level. Though
the more general relationship between TRIO and neurode-
velopmental disease has not been previously established,
the Deciphering Developmental Disorders Study35 has re-
ported TRIO as being one of twelve genes with ‘‘compelling
evidence for pathogenicity’’ across a number of neurodeve-
lopmental disorders even though a meta-analysis of 2,347
developmental disorder trios obtained a p value that did
not appear to reach genome-wide significance. TRIO is a
major regulator of neuronal development, and its functionn ¼ 500
e Poisson fitDNM TADA fitDNM-true
0.071 0.205 0.216 0.236
0.280 0.525 0.540 0.651
0.197 0.403 0.286 0.597
0.0003/10,000; 500/0.0015/8,000.
000;
00.
, 2015
Table 4. De-Novo-Mutation-Enriched Genes among Neuropsychiatric and Neurodevelopmental Disease
Disease
No. of
Females
No. of
Males Gene Gene Sizea (bp)
Observed No. of De Novo
Mutations
fitDNM Poisson Test TADAbTotal LOF Probably Damaging
ASD 184 764 SUV420H1 2,706 3 1 2 1:63106 5:593105 1:793106
EE 108 156 CDKL5 3,173 3 1 2 8:383109 7:473107 43108
SCN1A 6,134 7 3 4 2:3131017 5:2531014 <13109
STXBP1 1,975 5 1 4 9:4631015 1:3531011 <13109
GABRB3 1,573 4 0 4 2:5531011 1:593109 <13109
Combinedc 491 1,226 CDKL5 3,173 3 1 2 2:183106 1:473104 3:583106
SCN2A 6,218 7 3 4 2:4531011 1:983108 <13109
SCN1A 6,134 8 3 5 7:6631013 7:3331010 <13109
TRIO 9,522 5 0 5 2:063106 1:913104 1:173105
STXBP1 1,975 8 1 6 6:1731016 6:3431013 <13109
GABRB3 1,573 5 0 5 2:6231010 4:873108 13108
Listed are all genes that show a statistically significant (p value< 2:783106) enrichment of de novomutations in the three tests. No gene in the analysis of SZ and
severe ID was statistically significant in any of the three tests. Abbreviation is as follows: TADA, TADA-denovo.
aSize of all exomes (plus canonical splice sites).
bp values of TADA are estimated from 109 null simulations, thus extremely small p values can only be bounded by 13109.
cAnalysis combining the four neurodevelopmental diseases ASD, EE, SZ, and severe ID.is conserved through evolution.36 It has been shown that
TRIO is an ‘‘essential’’ mouse gene; complete loss of TRIO
in a mouse model results in abnormal neuronal migration
(MP: 0006009) and perinatal lethality (MP: 0011089), the
latter highlighting the gene’s importance in normal devel-
opment.37 Moreover, TRIO is among the FMRP-associated
genes,38 a set of genes that have been heavily linked and
significantly enriched for de novo mutations among the
neurodevelopmental disorders.7,8,39
Both Petrovski et al.40and Samocha et al.18 have high-
lighted SCN2A and TRIO as genes that are very intolerant
to functional variation in the general population. Such
genes have been shown to be increasingly associated
with Mendelian disease. SCN2A achieves a RVIS (Residual
Variation Intolerance Score) genic-intolerance percentile
score of 1.77% and TRIO achieves a genic-intolerance score
of 0.18%.40 Themutations in TRIO and SCN2A are summa-
rized in Table S1. The locations of mutations are displayed
in Figure 3 and Figure S3.
Control Samples
We also analyzed 728 trios with healthy offspring (340
males, 368 females, and 20 unknown). Among these 728
samples, 18 genes were observed to be recurrently hit by
de novomutations. Note that none of the genes implicated
in neurodevelopmental disorders (in Table 3) were
observed to have non-synonymous de novo mutations
among the 728 control trios. Analysis results for these 18
genes are summarized in Table S2. None of these genes
show significant enrichment of de novo mutations, either
by the Poisson test or fitDNM. Additionally, there was no
pattern in the ordering of p values between the Poisson
test and fitDNM.The AmerDiscussion
In this paper, we propose a statistical framework that incor-
porates mutation functionality when evaluating whether a
gene is enriched for de novo mutations in individuals
ascertained for a genetic disorder. In this framework, muta-
tions are modeled as having different probabilities of
disrupting a protein, leading to different weights for indi-
vidual de novo mutations in the resulting test statistic.
Severe disorders are often caused by increasingly damaging
mutations instead of milder mutations. Unlike TADA-
denovo, which only uses loss-of-function mutations and
probably damaging missense mutations in analysis, our
approach quantitatively evaluates all mutations across a
gene. As a result, it avoids ignoring potentially damaging
mutations while still leveraging information about their
predicted impact, potentially leading to an increase in
power. In this study, we observed such power increases
both in simulation studies and real data analyses. We
note, however, that the general TADA framework can
also incorporate inherited variation, which could signifi-
cantly improve its power for implicating causal genes
when inherited variation plays an important role in the
genetic architecture of the disorder.
In the analyses presented here, we use PolyPhen-2
scores to estimate the functional effect of missense de
novo mutations. However, our framework is flexible in
this respect and can easily accommodate other estimates
of variant functionality. For example, the predictions
of SIFT,14 conservation-based GERPþþ,41 and recently
published C scores15 can also be used to estimate variant
functionality. Furthermore, because these estimates areican Journal of Human Genetics 97, 272–283, August 6, 2015 279
Figure 3. Schematic Representation of TRIOconditioned on external data, misclassifying the func-
tional effect of a mutation will not affect the validity of
the test. Of course, power will be maximized when
in silico prediction of mutation deleteriousness is accu-
rately estimated.
In this manuscript, we have excluded indels and copy-
number variants from analyses because we do not believe
that current population-level de novo mutation rates are
well characterized for these classes of variation. Once
good estimates are available, our approach can easily be
adapted to incorporate these types of mutations. In fact,
it is simply a matter of expanding the set of possible muta-
tions that is summed over in the test statistic.
Our approach assumes that once a variant is damaging
to the protein product, its effect on disease is the same
regardless of the underlying mutation. However, this
assumption might not always hold. For example, stop-
gain mutations will always be damaging, but if the stop-
gain occurs at the beginning of gene, it could completely
knock out gene function, whereas a stop-gain that occurrs
at the end of the gene might not. Though this will not
affect the null behavior of our approach (i.e., impact type
I error), it could affect power. A natural way to deal with
this would be to have a mutation-specific risk parameter
at each site and test the global null hypothesis that all
these parameters are simultaneously equal to 1. This
approach would lead to a separate score equation for
each mutation type. These score equations could then be
combined for a gene-level test with standard burden42 or
kernel43 approaches commonly used in rare-variant associ-
ation methodology.
One interesting outcome of our study is that de novo
mutations within the TRIO gene have been implicated as
potential risk factors for developing neurodevelopmental
disorders. TRIO is a member of the Rho-guanine nucleotide
exchange factors (Rho-GEFs) and is named after its three
domains with putative enzymatic activity. There are a total
of 12 functional domains in TRIO, including two Dbl-280 The American Journal of Human Genetics 97, 272–283, August 6homology (DH) domains, two Pleckstrin-homology (PH)
domains, a divergent CRAL-TRIO domain, several spec-
trin-like repeats, two SH3 domains, an Ig-like domain,
and a serine-threonine-kinase domain (Figure 3).44 Among
all the domains, the DH-PH domain is the key enzymatic
unit for guanosine diphosphate (GDP) and guanosine
triphosphate (GTP) exchange. The two DH domains in
TRIO target different GTPases: the N-terminal DH domain
(DH1)mediates the GDP-GTP exchange of Rac1 and RhoG,
whereas the C-terminal DH domain (DH2) activates RhoA.
Several isoforms of TRIO, including TRIO A, B, C, and D,
have been identified. TRIO A, B, C, and D all contain the
first DH-PH GEF domain. TRIO A, B, and D are strongly ex-
pressed in brain tissue, whereas TRIO C is exclusively ex-
pressed in the cerebellum during development.45
The study of TRIO and its orthologs in C. elegans,
Drosophila, and mice demonstrates that DH1 of TRIO plays
a vital role in neurite outgrowth and axon guidance during
the development of the neuronal system. C. elegans TRIO-
like unc-73 is deeply involved in cell migration regula-
tion,46 whereas in Drosophila, dosage-sensitive interaction
between TRIO and the tyrosine-protein kinase Abl deter-
mines the axon pathfinding.47 TRIO knockout mice show
strong deficits in neural organization.48 Moreover, Estrach
et al. show that human TRIO can induce the neurite
outgrowth in PC12 cells through the DH1-dependent
RhoG activation. They also reveal that TRIO regulates the
nerve growth factor (NGF) differentiation pathway by
upstream signaling of RhoG.49
Defects in neuronal connectivity have been proposed to
contribute to the pathogenesis of ASD, IDs, and SZ.50,51
Indeed, neurite outgrowth and pathfinding of neuron
cells during development establish the positioning and
pattering of connections. Considering the role of TRIO,
especially DH1 in regulating the neurite outgrowth
and pathfinding, it suggests that TRIO could play an
important role in pathogenesis of neurodevelopmental
disorders., 2015
In the combined analysis of individuals ascertained for
a neurodevelopmental disorder, five de novo mutations
were identified in TRIO among 1,717 samples. As can be
seen from Figure 3, three of these mutations appear on
DH1, two in children with ASD, and one in a child with se-
vere ID. All of these mutations replace charged amino acids
with hydrophobic amino acids, which has high potential
to change the protein structure and deactivate DH1. This
DH1 dysfunction results in impaired downstream neurite
outgrowth and axon guidance functions.52
In light of all the evidence, TRIO is highlighted here as a
candidate risk gene for neurodevelopmental disorders and
provides further support to the concept of shared genetic
risk across neurodevelopmental disorders.Appendix A: Saddlepoint Approximation of the
Distribution Function of a Weighted Sum of
Independent Poisson Random Variables
LetXl;where l ¼ 1;.; p, be p independent Poisson random
variables such that EðXlÞ ¼ ll; where l ¼ 1;.; p. Let
Y ¼Ppl¼1clXl, where the cl values are known constants
and Z ¼Ppl¼1Xl. Note that we can write the cumulative
distribution function of Y as
PrðY%yÞ ¼
X
z
PrðY%y jZ ¼ zÞPrðZ ¼ zÞ: (Equation A1)
Note that, whereas the support of Y is infinite and not
defined on a lattice, the conditional distribution of Y given
Z is finite. In fact, it is easy to show that Y given Z is distrib-
uted as a linear combination of multinomial random
variables. Therefore, PrðY%yjZ ¼ zÞ can be accurately
approximated with the double saddlepoint approach of
Skovagaard.53 Before we are in a position to give Skova-
gaard’s approximation of PrðY%yjZ ¼ zÞ, we need to define
some of the involved quantities. The joint CGF of ðY;ZÞ is
given by
KY;Zðt; sÞ ¼
Xp
l¼1
ll

ecltþs  1:
The first and second derivatives of KY;Zðt; sÞ are given by
K0ðt; sÞ ¼
"Xp
l¼1
llcle
cltþs;
Xp
l¼1
lle
cltþs
#
and
K00ðt; sÞ ¼
2664
Pp
l¼1
llc
2
l e
cltþs Pp
l¼1
llcle
cltþs
Pp
l¼1
llcle
cltþs Pp
l¼1
lle
cltþs
3775;
respectively. Define the joint saddlepoint ðbt ;bsÞ as the root
to K0ðt; sÞ ¼ ðy; zÞ.
Let K0s denote the gradient of KY;Zðt; sÞ with respect to s
only, and let K00ss denote its corresponding Hessian, i.e.,
K0sðt; sÞ ¼
Pp
l¼1lle
cltþs and K00ssðt; sÞ ¼
Pp
l¼1lle
cltþs. DefineThe Amerthe marginal saddlepoint bs0 (from the marginal CGF of
Z) as the root of K0sð0; s0Þ ¼ z. Then Skovgaard’s approxima-
tion of PrðY%yjZ ¼ zÞ can be written as
PrðY%y jZ ¼ zÞ ¼ FðbwÞ þ fðbwÞ1bw  1bu

; bts0
(Equation A2)
where bw ¼ sgnðbt Þ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ2½½Kðbs0; 0Þ  bs0z  ½Kðbs;bt Þ  bsz bt yq ,
bm ¼ bt ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃK00ðbs;bt Þ=K00ssðbs0;0Þq . F and f are the standard
normal distribution and density functions, respectively,
and sgnðbt Þ is the sign of bt .
When bt ¼ 0, bw will equal 0, so that Equation A2 is un-
defined. To address this case, we use the method proposed
by Butler,54 which averages two close, nonsingular points
to approximate the distribution at the singularity.
We use Skovgaard’s approach to approximate PrðY%yj
Z ¼ zÞ. To approximate PrðY%yÞ, we use Equation A1,
where we truncate the summation when the terms become
small. Specifically, if we define f ðy; zÞhPrðYRy;Z ¼
zÞ ¼ PrðYRy jZ ¼ zÞPrðZ ¼ zÞ and Fðy; zÞhPzj¼0f ðy; jÞ,
then we truncate at z such that ðf ðy; z þ 1 Þ=Fðy; zÞÞ <
105 and approximate PrðY%yÞ by 1 Fðy; zÞ.Supplemental Data
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found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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